Status:
TERMINATED
Use of Convalescent Plasma for COVID-19
Lead Sponsor:
Northside Hospital, Inc.
Conditions:
COVID
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experienc...
Eligibility Criteria
Inclusion
- Documented COVID-19 infection by nasal pharyngeal sampling
- COVID-19 disease falling into one of the following groups:
- Critical disease: respiratory failure requiring mechanical ventilation, pressor support, or multiple organ dysfunction/failure
- Severe disease: tachypnea \>/=30 per min, O2 sats \</=93% at rest, PaO2/FiO2 index \</=300mmHg
- High Risk: upper respiratory symptoms but no radiographic evidence of disease, immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate to severe asthma history, severe COPD, morbid obesity (BMI \>/=40, age \>/=65 years
- Health Care Providers: health care providers at risk to exposure to COVID-19 infection or those with mild to non-severe disease
Exclusion
- History of IgA deficiency
- History of anaphylatic reaction to blood product transfusion including hypersensitivity to immunoglobulin therapy
Key Trial Info
Start Date :
July 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 14 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04408040
Start Date
July 14 2020
End Date
September 14 2021
Last Update
November 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northside Hospital
Atlanta, Georgia, United States, 30342